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Women who were q40 years of age on January 1st and a64 years of age on December 
31st of each year were extracted. Recipients with a diagnosis of breast cancer or
abnormal breast ﬁ ndings were excluded from the analyses using appropriate ICD-9
codes (174.XX, 233.0X, 238.3X, 239.3X). Data for women with claims for screening
mammography at any time during each calendar year were extracted using following 
CPT code: 76092. Results were reported by age group (40–49 years, 50–59 years, and 
60–64 years), race (White, Black, and others), county of residence, and geographic
area (metro, non-metro urban, non-metro rural) for each calendar year. RESULTS:
There was an estimated 12% increase in the screening mammography between 2000 
and 2005. A consistent increase in the mammography screening was observed during
study period (2000–2005) among women who were 50–59 years of age as compared 
to those between 40–49 and 60–64 years of age. Approximately 90% women who 
underwent screening mammography resided in either metro or non-metro urban areas.
CONCLUSIONS: Screening mammography trends differed among women based on 
demographic characteristics. Further research is needed to evaluate accessibility and 
knowledge among indigent women in order to develop effective breast cancer preven-
tion strategies.
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OBJECTIVES: The aim of this study was to identify health workers’ labor environ-
ment satisfaction in several oncology services from a tertiary referral center and two
second level-hospitals at the Social Security Mexican Institute (IMSS). METHODS: A
cross-sectional and descriptive study was performed within the IMSS in Guadalajara
City, Mexico. The health workers were interviewed using the work environment scale
(WES), this questionnaire contents 90 items through dichotomy answers (true/false)
to evaluate medical staff satisfaction among several item: involvement, cohesion, 
support, autonomy, organization, work-pressure, clarity, control, innovation, guidance 
and comfort. All workers interviewed attend mainly oncology patients. Internal con-
sistency was evaluated through Cronbach’s alpha and ANOVA to obtain statistical 
differences between health workers responses. This questionnaire was previously vali-
dated in Mexico. RESULTS: Eighteen physicians, 27 nurses, 7 medical assistants and
8 radiotherapy technicians were interviewed. The mean response for all health workers 
interviewed satisfaction level including all items was of 49% (23% to 78%), the lowest 
satisfaction level was for the comfort item (39%) and the highest was for the clarity 
item (59%). We did not ﬁ nd differences between medical staff specialties, with excep-
tion of nurses, whom were the lowest satisfaction level group (38%; p  0.001). 
However, statistical differences among all the hospitals studied in the assessment were
found. In the tertiary referral center physicians showed the lowest work environment
satisfaction in the cohesion item (40%; p  0.09) followed by nurses giving services 
to inpatients (38%; p  0.01). In second-level patients the lowest work environment 
satisfaction level was obtained in medical assistants in clarity items (37%; p  0.03)
and guidance (39%; p  0.08). CONCLUSIONS: Using the WES scale in three 
Mexican hospitals, the analysis showed that medical staff that attend oncology 
patients, are dissatisﬁ ed with their work environment. The less satisﬁ ed were nurses 
and medical assistants.
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OBJECTIVES: To understand Canadian and U.S. health system compliance with
cancer screening guideline information with respect to the age of screening initiation.
METHODS: Canadian and U.S. cancer screening generally identify ages when cancer
screening should be initiated. We use a regression discontinuity research design to
identify discrete increases in Canadian and U.S. cancer screenings in the past two 
years at the guideline recommended ages. Multivariate logistic regression analyses 
were performed using breast, prostate and colorectal cancer screening within the 
past two years as the dependent variables of interest. Logistic regression models also 
adjust for respondent demographic and socioeconomic characteristics. We analyze 
screening for adult individuals from the 2006 Behavioral Risk Factor Social Survey, 
2003 National Health Interview and 2003 and 2005 Canadian Community Health 
Surveys. RESULTS: Graphical and logistic regression analyses identiﬁ ed large statisti-
cally signiﬁ cant increases in cancer screening rates precisely at the U.S. guideline rec-
ommended screening initiation ages. U.S. breast, colorectal and prostate screenings
increase by 33%, 33% and 25% precisely at the guideline recommended ages(age 
40 for breast and age 50 for colorectal and prostate cancers). Similarly in Canada 
we found a 20% increase in breast cancer screening at age 50, the Canadian guideline 
recommended age for screening initiation. We did not ﬁ nd a discrete increase in the
Canadian colorectal cancer screening rate at the Canadian recommended screening
age of 50. CONCLUSIONS: U.S. and Canadian cancer screening utilization is gener-
ally consistent with each country’s guideline recommendations regarding age. The 
cross-country differences in screening identiﬁ ed in this study can potentially explain
cross-country differences in cancer mortality rates and affect interpretation of cross-
country cancer statistics. The similarity of other OECD cancer screening guidelines
to Canadian screening guidelines suggests that results from this study have broader 
applicability to comparisons of cancer statistics between U.S. and other OECD 
countries.
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OBJECTIVES: To understand the impact of U.S. cancer screening guideline informa-
tion on U.S. cancer screening and cancer detection. METHODS: We use an instru-
mental variables research design to identify the effects of breast, colorectal and
prostate cancer screening guideline information on cancer detection. U.S. guidelines
specify an age at which screening should begin, implicitly recommending that screen-
ing not occur for asymptomatic individuals below that age. We ﬁ rst estimate compli-
ance with guideline information from the difference in age-speciﬁ c screening rates just
below and above the ages at which clinical guidelines recommend that screening begin.
We then perform instrumental variables regression analyses to estimate the effect of 
guideline induced screening on cancer detection. U.S. cancer screening and incidence 
data (years 2000–2005) are derived from the Behavioral Risk Factor Social Survey,
the National Health Interview Survey and the SEER Program. RESULTS: Age-speciﬁ c 
screening rates from national BRFSS and NHIS survey data indicate that U.S. breast, 
colorectal and prostate cancer screening in the last year rise by 55%, 88% and 29% 
precisely at the guideline recommended ages(age 40 for breast cancer and age 50 for 
colorectal and prostate cancers). Results from instrumental variables analyses indicate
that a 1% point increase in screening at the guideline recommended ages leads to an 
additional case of breast and colorectal cancer detected per 100,000 individuals. The
substantial increase in prostate cancer screening did not have an identiﬁ able effect on 
prostate cancer detection. CONCLUSIONS: We used an instrumental variables strat-
egy to identify the impact of guideline information on cancer screening and detection. 
Guideline information induces substantial increases in breast, colorectal and prostate 
cancer screening but these changes only lead to increases in breast and colorectal
cancer detection. These results suggest that reductions in the use of the PSA test will 
result in substantial cost savings with minimal reductions in health.
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OBJECTIVES: There have been a number of new drugs and biologicals approved by
the FDA in the last ﬁ ve-years for the treatment of colorectal cancer (CRC). Objective 
of this study was to compare the initial treatments and overall medical costs for 
working-age persons with CRC before and after the introduction of these treatments.
METHODS: This retrospective cohort study was based on a large administrative
database and included patients with an ICD-9 diagnosis of CRC. We looked at indi-
viduals treated for CRC in the period prior to introduction of new chemotherapy and
biological agents (January 2002–December 2002) and the period after the introduction 
of two biologicals (bevacizumab and cetuximab) and one chemotherapy agent (oxali-
platin), (June 2004–May 2005). We assigned patients to stage of diagnosis based on 
treatment regimens. We identiﬁ ed 2545 patients (61% Stage III) with CRC in the 
pre-period and 4413 patients (59% Stage III) with CRC in the post-period. We esti-
mated mean total medical costs in the pre- and post- periods using the Kaplan-Meier 
sample average estimator. RESULTS: The predominant treatment regimen in the
pre-period for stage III CRC was 5-FU/Leucovorin (77%), while the pre-dominant
regimens the post-period were 5-FU/Leucovorin (36%) and FOLFOX (35%). The 
pre-dominant treatment regimen for stage IV CRC was IFL/FOLFIRI (50%), while 
the most common regiments in the post-period were IFL/FOLFIRI (22%) and
FOLFOX (23%). Additionally, over 14% of the patients received a biological agent 
in the post-period. There was also a signiﬁ cant increase in total medical costs over 
this time period. The mean costs for Stage III and Stage IV CRC patients increased 
from $56,187 in the pre-period to $101,049 in the post-period (p  0.001). CONCLU-
SIONS: The introduction of new treatments for CRC signiﬁ cantly changed the treat-
ment patterns for both Stage III and Stage IV CRC. These changes in treatment were 
accompanied by a signiﬁ cant increase total medical costs.
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OBJECTIVES: The occurrence of breast cancer causes signiﬁ cant morbidity and
mortality among patients and results in considerable economic impact on patients, 
health care payers, and society. The purpose of this study is to determine the trends
in the prevalence of breast cancer and associated health care utilization and costs
among an indigent population covered by a state Medicaid program. METHODS:
Retrospective analysis of a state Medicaid fee-for-service administrative claims dataset 
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for each calendar year from January 1, 2000 to December 31, 2005 was performed.
Breast cancer prevalence was determined based on the number of females (21–64
years) having at least one medical services claim with a primary diagnosis of breast 
cancer (ICD-9-CM codes 174, 233.0x, 238.3x, or 239.3x) at any time during the
calendar year. Corresponding medical services use and patterns of treatment were also
reported among females with breast cancer for each year. State Medicaid perspective
was used to calculate costs (2005 US dollars). RESULTS: From 2000 to 2005, the
number of female recipients with breast cancer increased from 789 to 1205, respec-
tively. Female recipients in the age group 45–64 years represented the highest propor-
tion in all the study years, increasing from 78.6% in 2000 to 83.9% in 2005.
Consistent with state population demographics, a majority (90%) of recipients in 
each year were white. Ofﬁ ce visits represented a large majority of medical services 
encounters (98%) and costs (90%) in each year. The average amount per recipient
paid by Medicaid for breast cancer-related medical services use increased from $2637
to $3570 between 2000 and 2005, respectively. The average cost per ofﬁ ce visit 
increased from $255/visit to $429/visit during the same period. CONCLUSIONS:
Breast cancer prevalence increased between 2000 and 2005. There has been a sub-
stantial increase in the cost impact associated with breast cancer on the State Medicaid 
program during the same period.
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OBJECTIVES: To compare dose-reduction patterns in patients with RCC treated
with FDA-approved tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib. 
METHODS: A retrospective analysis was conducted using data from a claims-based 
database (MarketScan MedStat) covering q18 million lives for 2002–2008 in all US
census regions. Patients with q2 claims for RCC (ICD9 189.0 or 198.0), continuous 
health care coverage, 180 days’ coverage before RCC diagnosis, and no claim for 
sorafenib or sunitinib before RCC diagnosis, who received a standard RCC initial
daily dosage of sorafenib 800 mg or sunitinib 50 mg and q2 consecutive dispensings,
were included. Initial episode was deﬁ ned as time from date of ﬁ rst drug-dispensing
to ﬁ rst of switch to another TKI, health care coverage end, treatment end, or 
March 31, 2008. Both patient and patient-time level analyses for dose reductions 
between treatments were conducted. RESULTS: Baseline demographics between
the groups (sorafenib, n  189; sunitinib, n  304) were similar except for a higher 
incidence of stroke (7.9% vs. 3.6%, P  .037) and other cancer site (93.7% vs. 87.8%, 
P  0.036) in the sorafenib group. Signiﬁ cantly more patients receiving sunitinib
required dose reductions compared with sorafenib (ﬁ rst 3 months: 23.0% vs 4.2%; 
complete initial episodes: 35.5% vs 16.9%; P  0.001 for both). For all episodes,
mean time to dose reduction was signiﬁ cantly longer for sorafenib than sunitinib (162
days vs 104 days, P  0.003). Signiﬁ cantly more dose reductions occurred within the
ﬁ rst 3 months with sunitinib than sorafenib (65% vs. 25%, P  0.001). Controlling
for different lengths of exposure time further conﬁ rmed that more dose reductions 
were observed in patients treated with sunitinib than with sorafenib (from 2–6 times 
greater, P  0.001). CONCLUSIONS: This retrospective US claims analysis showed
that signiﬁ cantly more dose reductions, including total number of patients and days,
were required in patients who initially received sunitinib than in those who received 
sorafenib.
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OBJECTIVES: To analyze baseline symptoms, comorbidities, and treatments in newly 
diagnosed RCC patients by age group. METHODS: Retrospective claims-based analy-
sis was conducted using MarketScan MedStat, a database covering all US census
regions, including q18 million lives for years 2002–2008. Patients with initial RCC
diagnosis in 2005–2007, q2 outpatient or q1 inpatient RCC claims (ICD9 189.0 or
198.0), continuous health care coverage, and 180 days coverage before diagnosis 
were included. Patients were followed from diagnosis until health care coverage end 
or June 30, 2008. Conditions, symptoms, and individual Charlson comorbidities were
assessed. Treatment was analyzed using prevalence and time to initiation in patients
 and q65 years old. RESULTS: Of 12,253 patients identiﬁ ed, 61.8% were male (mean 
age, 63 years old) and 51.0% were 65 years old. Overall, pain (59.6%), hypertension
(53.7%), anemia (23.2%), diabetes (23.6%), and chronic kidney disease (19.4%) were
most common comorbidities reported. Most comorbidities were prevalent in q65 years 
old than 65 years old: notably, cerebrovascular disease (8.7% vs. 3%; P  0.001), 
acute myocardial infarction (2% vs 0.7%; P  0.001), and chronic renal failure (9.3% 
vs. 6%; P  0.001). In 65 and q65 groups, most commonly used treatments were 
nephrectomy (53.4% vs. 40.4%; P  .001), intravenous chemotherapy (11.7% vs. 
13.3%; P  0.0079) and oral chemotherapy (10.5% vs. 13.3%; P  0.0001), although 
less than 4% of patients in either group received FDA-approved oral agents sorafenib 
or sunitinib. For 65 and q65 groups, respectively, mean time from RCC diagnosis
to: nephrectomy, 25 and 31 days; radiotherapy, 170 and 177 days; intravenous che-
motherapy, 154 and 181 days; sorafenib, 220 and 247 days; sunitinib, 221 and 205
days. CONCLUSIONS: Baseline comorbidities and symptoms were more common in
RCC patients q65 years old than those 65 years old. Nephrectomy was used more
frequently in patients 65, probably because of comorbidities in older patients. In 
contrast, systemic treatment was similar in both groups.
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OFF-LABEL USE OF ONCOLOGY DRUGS IN A COMMUNITY
ONCOLOGY EMR DATABASE
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OBJECTIVES: The objective of this study was to examine the utilization patterns of 
cancer medications beyond their labeled indications approved by the FDA in commu-
nity oncology practices. METHODS: Drug prescription information from a commu-
nity oncology data warehouse was used for two separate analyses. Patients were
categorized according to whether they had an ICD-9 diagnosis code for one of four 
cancer types including lung, breast, bladder or gastric, and having no other malig-
nancy. The frequency of use of various oncology drugs was examined for each of these 
groups, against a set of medications that were FDA-approved for these indications or 
were recommended by NCCN guidelines. In the second analysis, patients with a single
malignancy, who received any of the ﬁ ve oncology drugs (paclitaxel, vinorelbine,
rituximab, bevacizumab) and gemcitabine, were counted. Comparisons were then 
made against the cancer indications for which these agents were approved by the FDA. 
RESULTS: Seventy-eight percent of breast and 95% of lung cancer patients received
medications approved for these indications, while 68% and 75% also received drugs
that were not approved by the FDA for those conditions. More than 99.7% of these
patients received agents recommended on NCCN guidelines. None of the bladder
cancer patients and only 5% of gastric cancer patients received drugs approved for
these indications, while 97% and 95% of them received guideline-recommended 
drugs. Only half of the patients given paclitaxel or bevacizumab received these for an 
FDA-approved indication. In the case of vinorelbine and gemictabine, the proportion
was lower at 30% and 40% respectively, while it was higher for rituximab at 60%. 
CONCLUSIONS: Oncologists’ choice of drugs is driven by evidence-based guidelines,
independent of FDA approval. There is a high and varying proportion of off-label use 
across oncology medications and cancer types.
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OBJECTIVES: Hepatitis B virus infected over 2 billion people worldwide, and 350 
million suffering from chronic HBV infection. The prevalence of chronic HBV infec-
tion is high in Asia and most of Africa. Kushenin injection as a new traditional Chinese
medicine is now widely used for chronic HBV treatment in China. The objective of 
this study was to compare the effectiveness between Kushenin and western medicines 
on patients with chronic HBV. METHODS:  Based on a pilot study of patient interview 
at one hospital setting, we identiﬁ ed key outcome measurements of effectiveness 
related to Kushenin and western medicine, including ALT recovery rate and negative
conversion rate of HBeAg. Consequently, we performed a systematic literature review 
using computer-based search-engines such as MEDLINE (1966 to 2007), EMBASE 
(1966 to 2006), OVID (1965 to 2006), the Chinese Biomedical Database (CBM) (1978 
to 2006) and CNKI (China National Knowledge Infrastructure) (1994 to 2007). From 
available data, both interferon and lamivudine were selected as western medicines to 
compare with Kushenin regimen. A Meta-analysis was performed using a software
program of Reviewmanager 4.2. RESULTS: A total of 15 published clinical studies 
involving 1396 patients met inclusion criteria for the meta-analysis. Comparing to 
interferon alone regimen, Kushenin showed no signiﬁ cant differences in terms of ALT 
recovery rate [relative risk, RR  0.96; 95% conﬁ dence interval (CIs),0.86–1.09] and 
negative conversion rate of HBeAg (RR  0.85; 95%CIs, 0.69–1.05). Meanwhile, 
kushenin combined with lamivudine showed better effectiveness in term of ALT
recovery rate (RR  1.77; 95%CIs,1.38–2.26) and negative conversion rate of HBeAg 
(RR  2.58; 95% CIs, 1.81–3.68) compared with lamivudine alone. CONCLUSIONS:
Integrated Kushenin plus lamivudine showed better clinical outcomes in ALT recovery
rate and HBeAg negative conversion rate. Further evidence-based analysis is required
due to low quality of randomization procedure in clinical trials and insufﬁ cient study
patients for treating chronic HBV with kunshenin.
